Revenue distribution by industry:

• Life Sciences: approx. 80%
• Healthcare: approx. 15%
• Other industries: approx. 5%

TOP 3 markets and their percentage shares:

• USA: approx. 55%
• Europe: approx. 25%
• Asia-Pacific: approx. 15%

Veeva Systems Inc. generates the majority of its revenue from the Life Sciences industry, particularly through its cloud-based software solutions developed for pharmaceutical and biotechnology companies. The U.S. market is the largest single market for Veeva, followed by Europe and the Asia-Pacific region, which also make significant contributions to the total revenue. This distribution reflects the company's strong presence and focus on the global Life Sciences markets.

Production Sites: Mainly in the USA

Veeva Systems Inc. is a leading company in the field of cloud-based software solutions for the life sciences industry. The company develops and distributes its products mainly in the USA, where the majority of its development and production activities are also concentrated.

Since Veeva Systems is a software company, physical production sites are less relevant compared to traditional manufacturing companies. The main activities include software development and maintenance, which are carried out by specialized teams in various branches worldwide.

Revenue Growth: Estimated 10-12% annually (2025-2027)

Veeva Systems Inc. pursues a growth strategy focusing on expanding its product portfolio and deepening its market presence. A central element of this strategy is the continuous innovation in its cloud-based solutions for the life sciences industry.

The company heavily invests in research and development to develop new products that meet the changing needs of the industry. This includes both expanding existing platforms and introducing new applications that support the entire lifecycle of drugs and clinical trials.

In addition, Veeva is focusing on geographical expansion, especially in emerging markets, to attract new customers and strengthen existing relationships. Partnerships and strategic alliances with other technology companies and industry leaders also play an important role in their growth strategy.

Through these measures, Veeva expects to further strengthen its market leadership and achieve sustainable growth.

Main materials: Software and cloud services
Import countries: USA (headquarters), no physical raw material imports

Veeva Systems Inc. is a company specializing in cloud-based software solutions for the life sciences industry. As a technology company, Veeva Systems does not import physical raw materials or materials in the traditional sense.

Veeva's main resources are software development, data management, and cloud computing services. These services are mainly developed and provided in the USA. Therefore, Veeva's focus is on technological and human resources, not on physical imports.

Market share in Life Sciences CRM: Over 50% (2025, estimated)
Customer satisfaction: High ratings in industry surveys (2024)
Research & Development: 15% of revenue (2024)

Veeva Systems Inc. has a significant competitive advantage in the field of cloud-based software solutions for the life sciences industry. The company has established itself as a market leader in Customer Relationship Management (CRM) for this sector, with an estimated market share of over 50%.

An essential factor for this advantage is the high customer satisfaction that Veeva achieves through specialized solutions and continuous innovations. The company invests about 15% of its revenue in research and development, enabling it to continuously improve its products and tailor them to the specific needs of the industry.

In addition, Veeva benefits from strong customer loyalty and an extensive ecosystem that makes it difficult for new competitors to enter the market. The strategic focus on the life sciences industry and the ability to integrate regulatory requirements further strengthen this advantage.

Institutional investor share: approx. 75% (estimated for 2025 based on historical data)

Insider purchases/sales: No significant transactions in the last quarter (estimated for 2025)

The institutional investor share in Veeva Systems Inc. has remained stable at around 70-80% in recent years. This high participation indicates a strong trust of institutional investors in the company, often associated with stable financial performance and a solid market position.

Regarding insider transactions, there were no significant purchases or sales in the last quarter. This may suggest that the management is confident in the current valuation of the company and sees no need to change their positions. Such information is important for investors to assess the management's confidence in the company's future development.

Market share of Veeva Systems Inc.: 25% (estimated for 2025)

Main competitors and their market shares:

1. Veeva Systems Inc.: 25%
2. IQVIA Holdings Inc.: 20%
3. Oracle Corporation (Health Sciences): 15%
4. Medidata Solutions (part of Dassault Systèmes): 12%
5. SAP SE (Health Solutions): 10%
6. Parexel International Corporation: 8%
7. Cerner Corporation (part of Oracle): 5%
8. Other smaller providers: 5%

Veeva Systems Inc. has a significant moat, mainly based on its specialization in the life sciences industry. The company offers specialized cloud-based solutions tailored to the specific needs of this sector, which implies high switching costs for customers.

Compared to its competitors, Veeva has the advantage of focusing exclusively on life sciences, while companies like Oracle and SAP offer broader software solutions that are not as industry-specific. This allows Veeva to provide specialized features and services that are highly valued by customers in the life sciences sector.

However, companies like IQVIA and Medidata also hold strong positions in the market, as they offer comprehensive data and analytics capabilities as well as integrated solutions that are attractive to many customers. These companies might have a stronger moat in certain areas, especially concerning data and analytics integration.

Overall, Veeva Systems Inc. remains a leading provider with a strong moat due to its specialization and deep understanding of the life sciences industry, but they must remain vigilant to maintain their edge over the more versatile offerings of the competition.

Revenue growth: 17% (2024) Profit growth: 15% (2024) Market share in the Life Sciences sector: 30% (2024)

Veeva Systems Inc. shows strong revenue and profit growth, indicating a solid business strategy and a strong position in the Life Sciences sector. The company has continuously expanded its market share through innovative cloud solutions and an extended product range.

The focus on the Life Sciences sector, which continues to benefit from digitization, provides Veeva Systems with stable growth potential. Additionally, in recent years, the company has significantly expanded its customer base, indicating high customer satisfaction and strong customer loyalty.

Analysts see Veeva Systems as a promising investment, especially due to the continuous investments in research and development, positioning the company well for future innovations.

Dividend: No payout (as of 2025)

Veeva Systems Inc. has traditionally not distributed any dividends to its shareholders. The company typically reinvests its profits in the growth and expansion of its business activities. This strategy is not uncommon among technology companies, as they often aim for high growth rates and require capital for research and development as well as market expansion.

The reliability of the payout is therefore not relevant, as Veeva Systems does not follow a dividend policy. Investors who invest in Veeva usually do so because of the potential for share price increases and not because of the dividend yield.